REGENXBIO stock reports 60 percent three-year eye study response

Published on 09/25/2026 at 16:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

REGENXBIO stock traded at USD 7.22 on September 25, 2026, while Q2 revenue reached USD 108.0 million. EPS was USD 0.43 versus USD 0.08 consensus on August 6, 2026.

RGNX, US75901B1052, Illustration mit AI erstellt.

REGENXBIO stock (ISIN US75901B1052) was trading at USD 7.22 on Nasdaq on September 25, 2026, down 0.31 percent from the prior close. The company also reported three-year data showing that 60 percent of Dose Level 3 participants in its ALTITUDE eye-disease study achieved a greater than two-step improvement in disease severity scores.

Three-year eye data strengthens the case

According to PR Newswire on September 24, 2026, six of ten Dose Level 3 participants with three-year visits reached that improvement without additional diabetic retinopathy treatment. The participants had no vision-threatening events, while no intraocular inflammation was observed through three years in 17 participants.

The data came from Phase II ALTITUDE, which is testing surabgene lomparvovec, also known as sura-vec or ABBV-RGX-314, for non-proliferative diabetic retinopathy. The program is being developed with AbbVie and uses a one-time administration in an office setting.

Q2 revenue jumped on milestone income

Stock Titan reported on August 6, 2026, that second-quarter 2026 revenue reached USD 108.0 million, compared with USD 21.4 million in the second quarter of 2025. Net income was USD 22.7 million, or diluted EPS of USD 0.43, after a USD 70.9 million net loss a year earlier.

Quarterly EPS also exceeded the USD 0.08 consensus estimate by USD 0.35, according to MarketBeat. The figures show how strongly milestone income influenced the quarter, while the pipeline remains dependent on clinical execution.

Analyst target remains above the share price

Robert W. Baird reduced its price target for REGENXBIO from USD 32.00 to USD 29.00 and maintained an Outperform rating in a report dated August 25, 2026, according to MarketBeat. That target is materially above the USD 7.22 Nasdaq price, leaving clinical outcomes and milestone revenue as the central valuation variables.

RGNX trades within a wide yearly range

RGNX was trading at USD 7.22 on Nasdaq on September 25, 2026, at 10:52 a.m. ET. The stock's 52-week range was USD 5.46 to USD 16.19, while market capitalization stood at USD 373,125,674.